Four analysts shared their evaluations of Amdocs (NASDAQ:DOX) over the past three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, offering a look at the changing sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat bullish | Indifferent | Somewhat bearish | Bearish | |
|---|---|---|---|---|---|
| Total reviews | 3 | 1 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1 million ago | 1 | 0 | 0 | 0 | 0 |
| 2M ago | 0 | 0 | 0 | 0 | 0 |
| 3M ago | 2 | 0 | 0 | 0 | 0 |
Analyst evaluations of twelve-month price targets provide additional insights, showing an average price target of $93.5, with a high estimate of $97.00 and a low estimate of $88.00. This current average is down 8.33% from the previous average price target of $102.00.
Diving into analyst ratings: an in-depth investigation
The perception of Amdocs by financial experts is analyzed based on recent actions by analysts. The following summary presents the top analysts, their recent evaluations and adjustments to ratings and price targets.
Key insights:
Understanding these analyst evaluations alongside key financial indicators can provide valuable insights into Amdocs’ market position. Stay informed and make informed decisions with our Rating Chart.
Stay up to date with Amdocs analyst reviews.
Discovering Amdocs: up close
Financial insights: Amdocs
Market Capitalization Analysis: The company’s market capitalization, which is below industry benchmarks, reflects a smaller size compared to peers. This positioning can be influenced by factors such as growth expectations or operational capacity.
Sales growth: Amdocs’ revenue growth over 3 million years has faced challenges. As of September 30, 2025, the company experienced a decline in sales of approx -8.99%. This indicates a decline in the company’s sales. Compared to others in the information technology sector, the company faces challenges and achieves a growth rate that is lower than the average of its peers.
Net margin: Amdocs’ net margin is impressive and exceeds industry averages. With a net margin of 8.22%, the company exhibits strong profitability and effective cost management.
Return on Equity (ROE): Amdocs’ ROE exceeds industry standards and underlines the company’s exceptional financial performance. With an impressive 2.73% ROE makes the company use equity effectively.
Return on Assets (ROA): Amdocs’ ROA exceeds industry benchmarks and reaches 1.5%. This means efficient asset management and strong financial health.
Debt management: Amdocs’ debt-to-equity ratio is below industry norms, indicating a healthy financial structure with a ratio of 0.24.
Analyst ratings: what are they?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish “analyst ratings” for stocks. Analysts typically review and rate each stock once per quarter.
In addition to their ratings, some analysts expand their insights by issuing forecasts for key metrics such as earnings, revenue, and growth estimates. This additional information provides further guidance for traders. It is crucial to recognize that analysts, despite their specialization, are human and can only make predictions based on their beliefs.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
#Analyst #Ratings #Amdocs #Amdocs #NASDAQDOX